TENAYA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • July 9th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
UNDERWRITING AGREEMENT [•] Shares TENAYA THERAPEUTICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHAREUnderwriting Agreement • July 26th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
TENAYA THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • August 10th, 2022 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
UNDERWRITING AGREEMENT 22,613,307 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 6,236,693 SHARES OF COMMON STOCK TENAYA THERAPEUTICS, INC.Underwriting Agreement • November 17th, 2022 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
June 25, 2021 Timothy Hoey c/o Tenaya Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Tim:Employment Letter Agreement • July 9th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • Colorado
This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Tenaya Therapeutics, Inc. (the “Company” or “we”), effective as of the effective date of the Company’s registration statement relating to the Company’s initial public offering (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date.
SUMMARY OF BASIC LEASE INFORMATIONLease • July 9th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
INDUSTRIAL LEASE – MULTI-TENANT by and between TERRENO PARK UNION CITY LLC and TENAYA THERAPEUTICS, INC. Dated: February 12, 2021Industrial Lease • July 9th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances)
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LICENSE AGREEMENTLicense Agreement • July 9th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • Texas
This License Agreement (this “Agreement”) is dated as of January 10, 2020 (the “Effective Date”) by and between The Board of Regents (“Board”) of the University of Texas System (“System”), an agency of the State of Texas, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System (“Licensor”), and Tenaya Therapeutics, Inc., a Delaware corporation (“Licensee”). Licensor and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 17, 2020Investors’ Rights Agreement • July 9th, 2021 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of December 17, 2020, and is between Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A (each, an “Investor” and collectively, the “Investors”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 6th, 2024 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances)
by Bank, the “Prime Rate” shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of North Carolina (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero percent (0.0%) per annum, such rate shall be deemed to be zero percent (0.0%) per annum for purposes of this Agreement.
Leone Patterson June 18, 2021 Dear Leone:Tenaya Therapeutics, Inc. • July 9th, 2021 • Biological products, (no disgnostic substances)
On behalf of Tenaya Therapeutics, Inc. (“we” or the “Company”), I am pleased to invite you to join the Company on the terms and conditions set forth in this letter agreement (the “Agreement”), effective as of the date on which you commence employment with the Company (the “Effective Date”). We look forward to the possibility of your joining our Company.
FIRST AMENDMENT TO LEASELease • August 8th, 2024 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO LEASE ("First Amendment") is made and entered into as of June 14, 2024, by and between HCP OYSTER POINT III LLC, a Delaware limited liability company ("Landlord"), and TENAYA THERAPEUTICS, INC., a Delaware corporation ("Tenant").
ContractPurchase Stock • November 6th, 2024 • Tenaya Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
